Abstract
The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Reviews on Recent Clinical Trials
Title:Gut Microbiota and Alcoholic Liver Disease
Volume: 11 Issue: 3
Author(s): Emidio Scarpellini, Mariana Forlino, Marinella Lupo, Carlo Rasetti, Giammarco Fava, Ludovico Abenavoli and Adriano De Santis
Affiliation:
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Abstract: The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Export Options
About this article
Cite this article as:
Scarpellini Emidio, Forlino Mariana, Lupo Marinella, Rasetti Carlo, Fava Giammarco, Abenavoli Ludovico and De Santis Adriano, Gut Microbiota and Alcoholic Liver Disease, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160810100538
DOI https://dx.doi.org/10.2174/1574887111666160810100538 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Characterization of the Nutritive Value of Flour Made from Acai (Euterpe oleracea, Mart.) Seeds
The Natural Products Journal The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Are Catechins, Polyphenols in Tea, Good for Your Health?
Current Nutrition & Food Science Depression, Serotonin and Tryptophan
Current Pharmaceutical Design The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Genetic Polymorphisms of Human Sulfate Transporters
Current Pharmacogenomics Homochiral Drugs: A Demanding Tendency of the Pharmaceutical Industry
Current Medicinal Chemistry Rabbit as an Animal Model for Pharmacokinetics Studies of Enteric Capsule Contains Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles
Current Clinical Pharmacology Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening?
Combinatorial Chemistry & High Throughput Screening Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry Sulforaphane Protects Small Intestinal Mucosa From Aspirin/NSAID-Induced Injury by Enhancing Host Defense Systems Against Oxidative Stress and by Inhibiting Mucosal Invasion of Anaerobic Enterobacteria
Current Pharmaceutical Design Premature Aging in Fibromyalgia
Current Aging Science Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Genetic Techniques for Pharmacogenetic Analyses
Current Pharmaceutical Design Phytosterols: Perspectives in Human Nutrition and Clinical Therapy
Current Medicinal Chemistry The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets